Loading patent…
AssigneePhosimmune, Inc.
InventorsDonald F. Hunt, Jeffrey Shabanowitz, Jennifer Cottine, Ann M. English, Andrew Norris, Victor H. Engelhard, Mark Cobbold, Kara L. Cummings, Angela Zarling, Rebecca C. Obeng, Jie Qian
Estimating the term…
A set of phosphorylated peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of melanoma cells. They have the potential to (a) stimulate an immune response to the cancer, (b) to function as immunotherapeutics in adoptive T-cell therapy or as a vaccine, (c) to facilitate antibody recognition of the tumor boundaries in surgical pathology samples, and (d) act as biomarkers for early detection of the disease. Phosphorylated peptides are also presented for other cancers.
An isolated and purified phosphopeptide consisting of between 8 and 50 contiguous amino acid residues derived from a native human protein, said phosphopeptide comprising a sequence selected from SEQ ID NO:
6-7. (canceled)
17-22. (canceled)
24-26. (canceled)
28-29. (canceled)
A kit for measuring a phosphoprotein, said phosphoprotein comprising a sequence selected from SEQ ID NO:
31-33. (canceled)
A method, comprising:
35-42. (canceled)
An in vitro composition comprising dendritic cells made by the method of claim 33, wherein the dendritic cells are loaded with a phosphopeptide consisting of between 8 and 34 contiguous amino acids comprising a sequence selected from SEQ ID NO:1-1391, said phosphopeptide including at least one serine, threonine, or tyrosine residue that is phosphorylated, wherein when the sequence is selected from SEQ ID NO:1266-1297, the phosphopeptide is phosphorylated with a non-hydrolyzable phosphate group.
44-47. (canceled)
A synthetic phosphopeptide consisting of from 10-50 amino acid residues, comprising the sequence RVAsPTSGVK (SEQ ID NO:
49-50. (canceled)
Dependencies are inferred from the claim text.